Manufacturers who do little business outside the US shouldn’t assume they don’t need to think about the Foreign Corrupt Practices Act, two attorneys for Arnall Golden Gregory said in a Jan. 25 webinar.
“DOJ has been very creative in expanding the reach of FCPA,” attorney Michael Burke warned. For example, the government’s evidence in Teva Pharmaceutical Industries Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?